PROPRANOLOL
Pediatric Cancer
Assistance Publique Hopitaux De MarseilleSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Pediatric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
Nivolumab Australian & New Zealand Children's Haematology/Oncology Group | Phase 2 | B |
Carboplatin Samsung Medical Center | Phase 2 | B |
gw786034 Samsung Medical Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
PROPRANOLOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →